PISCATAWAY, N.J., June 8, 2006 - A recent study entitled "Effects of Chemical Form of Selenium on Plasma Biomarkers in a High-Dose Human Supplementation Trial" published in the April 2006 edition of Cancer Epidemiology, Biomarkers & Prevention, a journal distributed by the American Association for Cancer Research, found that bioavailability of selenium was greatest for selenomethionine (as Selenium SeLECT from Sabinsa Corporation), less for high-selenium yeast and the least for sodium selenite.
"This study further substantiates the fact that selenium in the form of selenomethionine, specifically our Selenium SeLECT compound, is more available to be absorbed and used by the body," noted Vladimir Badmaev, M.D., Ph.D., vice president of scientific and medical affairs, Sabinsa Corporation. "Additionally, some of the participants had total daily intakes of more than 800 micrograms of selenium over the course of the study and showed no signs of selenium toxicity despite the fact that 800 micrograms is well above the recognized safe upper limit set by the Institute of Medicine."
This study of selenium-replete subjects compared the effects of supplementing three forms of selenium - selenomethionine, high- selenium yeast and sodium selenite - in moderate to high doses on selenium biomarkers as measured by urinary excretion after 16 weeks of supplementation. Plasma selenium concentration was responsive to supplements in proportion to their selenomethionine content. The increment in plasma selenium concentration during supplementation can be used to estimate compliance and ensure safety of selenomethionine supplements given in chemoprevention studies.
Cancer Epidemiology, Biomarkers & Prevention publishes original, peer- reviewed research on cancer causation, mechanisms of carcinogenesis, prevention and survivorship. Topics include descriptive, analytical, biochemical and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention.
Selenium SeLECT is Sabinsa Corporation's branded L-(+)- Selenomethionine compound, the most bioavailable, pure and safe form of selenium. Selenium is a trace mineral that is found naturally in soil and has been shown to have several positive health benefits. When consumed, selenium enters the body to form selenoproteins and glutathione, the body's antioxidant immune system detoxifier.
Currently, the National Cancer Institute (NCI) is using Selenium SeLECT for its Selenium and Vitamin E Cancer Prevention Trial (SELECT), a 12-year study focused on the role of selenium and vitamin E, both separately and together, in the prevention of prostate cancer. Shortly after this study began the following qualified health claim was issued by the FDA, "selenium may reduce the risk of certain cancers. Some scientific evidence suggests that consumption of selenium may reduce the risk of certain forms of cancer. However, FDA has determined that this evidence is limited and not conclusive." Additionally, NCI is conducting the Prevention of Alzheimer's by Selenium SeLECT and Vitamin E (PREADVISE) trial in conjunction with SELECT. This study is researching the role of selenium and vitamin E in preventing memory damage with age, including Alzheimer's and other diseases that can affect the brain.
Selenium SeLECT was chosen for these NCI studies because of its high quality. The worldwide quality standard or USP monograph for selenomethionine is based on Selenium SeLECT. For more information visit www.seleniumselect.com.
Sabinsa Corporation, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals. Sabinsa's mission is to provide alternative and
complementary natural products for human nutrition and well-being.
Over the past nine years, Sabinsa has brought to market more than 30 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified
Kosher. For more information visit www.sabinsa.com.
For a complete copy of this study, please contact Courtney Jacobs at 801-538-0777 ext. 102 or [email protected].
# # #